Clinical Trial Update: Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) [Phase 2]

View source ↗

Summary

Phase 2 trial update of zilebesiran as add-on therapy to standard antihypertensive medications in patients with high cardiovascular risk and hypertension not ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Zilebesiran

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: High Cardiovascular Risk, Hypertension | Phase 2 | Status: COMPLETED